EPO and chronic kidney disease: Previous studies showed FG‐4592 improved anemia of CKD by increasing Epo and reducing serum hepcidin in the patients.[32, 33] Interestingly, we found intestine serves as the additional important effective organ of FG‐4592, which functions to activate duodenal Fpn expression by stabilizing Hif2α.